September, 2015: Plasma Gelsolin Patent Portfolio Further Expands Coverage in Asia - BioAegis Therapeutics

Skip to content

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

September, 2015: Plasma Gelsolin Patent Portfolio Further Expands Coverage in Asia

September 28, 2015

Patents Granted for Renal Failure in Japan and Inflammation in Korea

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – September, 2015) BioAegis Therapeutics announced today patents were recently granted covering plasma gelsolin uses for renal failure in Japan and inflammation in Korea. Further applications in jurisdictions in Asia are also pending.

Stay informed of our latest discoveries and news.

EMAIL

GENERAL NEWS/MEDIA

August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS)

August 20, 2025

June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

June 17, 2025

June 10, 2025: BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)

June 10, 2025

EVENTS

March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference

March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM)

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
685 US Route 1
North Brunswick, NJ 08902

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US

Twitter Linkedin Youtube Medium

©2024 BioAegis® Therapeutics Inc.
Privacy Policy | Code of Business Conduct and Ethics | Terms of Use

error: Content is protected !!